Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

NCT04578834 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

518

Enrollment

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy

Interventions

DRUG: Placebo
DRUG: LNP023

Sponsor

Novartis Pharmaceuticals